Acetyladriamycin review

Acetyladriamycin is an anthracycline chemotherapy agent used in the interposition of some cancers.


It is commonly administered as a interposition for acute myeloid leukemia and acute lymphatic leukemia. It is also a new interposition for Karposi's sarcoma, an acquired immunodeficiency syndrome-related cancer of the skin and mouth but can also spread elsewhere. It works as a cytotoxic agent - preventing cancer cells from reproducing and eventually killing them off. It may also be used as part of a greater cancer interposition in combination with other medications.

Acetyladriamycin is available as daunorubicin hydrochloride and daunorubicin citrate liposome. The liposomal formulation of the medication is structured such that the medication is contained within lipid (fat) molecules. This special formulation is able to penetrate eubstance tissue and reach cancer cells easily because of its smaller size and special structure, it also remains longer in the eubstance than daunorubicin citrate and is generally considered to be less prone to side effects. Acetyladriamycin's liposomal formulation is available as an injection under the brand name DaunoXome in the United States.

This medication is often prescribed as part of interposition for acute myeloid leukemia and acute lymphatic leukemia. It is also a recently approved interposition for the rare Karposi's sarcoma.


To prepare Acetyladriamycin for administration, the vial must be filled with 4 mL of sterile water for injection and slowly turned until the material has been completed dissolved in the water. Each vial can provide 20 mg of Acetyladriamycin, and the desired dose is then drawn using a syringe already containing 10 to 15 mL of 0.9% sodium chloride solution and injected in a rapidly flowing 5% dextrose injection or 0.9% sodium chloride solution. Acetyladriamycin should not be administered with other medications or with heparin.


Dosage of Acetyladriamycin varies depending on the affected role's condition as well as their age, eubstance surface area and medical history.

For affected roles below 60 years of age suffering from acute nonlymphocytic leukemia, a dose of 45 mg/m2/day of Acetyladriamycin IV infusion is given on the first 3 days of the first course of interposition and again on the first 2 days of the succeeding courses. Aside from Acetyladriamycin, another medication called cytosine arabinoside should also be administered in 100 mg/m2/day IV infusion dose each day for 7 days for the first course of interposition and 5 days for the following courses of interposition.

For affected roles 60 years old and above, the dose is lowered to 30 mg/ m2/day IV infusion on the first 3 days of the initial interposition course and again on the first 2 days of the following courses. Cytosine arabinoside doses for the interpositions remain similar to those administered to affected roles below 60 years of age.

Dosage for children also vary - and for children suffering from lymphocytic leukemia, a dose of 25 mg/m2 Acetyladriamycin IV infusion and vincristine 1.5 mg/m2 should be given every first day of the week along with prednisone 40 mg/m2 PO every day. A complete remission of cancer may already be observed after four courses of this interposition, but if remission remains partial, an additional 2 courses may be administered to facilitate complete remission. For children younger than 2 years of age or those whose eubstance surface area is below 0.5 m2, it is recommended to measure doses of Acetyladriamycin with respect to weight rather than eubstance surface area.


Nausea and vomiting may be experienced soon after interposition and may last for 2 days. Complete or partial hair loss may also be experienced, usually starting 3 to 4 weeks into the interposition.

A dangerous side effect that may occur is the lowering of resistance against infections. If you feel that you have a fever higher than 38 oC (100.5 oF) or feel generally unwell, seek immediate medical attention.

Other side effects include bruising and bleeding, changes in the color of urine and nails, sensitivity to the sun, fatigue and changes in taste.


Acetyladriamycin should only be administered through a vein along with other IV fluids, and must not be injected into muscle tissue or just underneath the skin. Do not inject the medication into the spinal cavity as this may cause serious nerve damage. Notify doctors if you observe any redness or experience pain, itching or swelling at or around the site of injection. Rarely, Acetyladriamycin may also increase the risk for cardiovascular problems, which includes heart failure, during or even months and years after completion of interposition.

Acetyladriamycin has the following structural formula:

Chemical structure of acetyladriamycin

 Molecular formula of acetyladriamycin is C27H29NO10
 Chemical IUPAC Name is 8-acetyl-10-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
 Molecular weight is 527.52 g/mol

Generic name: Daunorubicin

Brand name(s): Anthracyline, Cerubidin, Cerubidine, Daunamycin, Daunarubicinum, Daunoblastin, Daunomycin, Daunorrubicina, Daunorubicine, Daunorubicinum, Daunoxome, Leukaemomycin C, Ondena, Rubidomycin, Rubomycin C

  Your Acetyladriamycin review